This company has been marked as potentially delisted and may not be actively trading. Miragen Therapeutics (MGEN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MGEN vs. XGN, MDXH, SERA, OPGN, BDSX, BNR, ENZ, BGLC, ACON, and NTRAShould you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include Exagen (XGN), MDxHealth (MDXH), Sera Prognostics (SERA), OpGen (OPGN), Biodesix (BDSX), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), BioNexus Gene Lab (BGLC), Aclarion (ACON), and Natera (NTRA). Miragen Therapeutics vs. Exagen MDxHealth Sera Prognostics OpGen Biodesix Burning Rock Biotech Enzo Biochem BioNexus Gene Lab Aclarion Natera Miragen Therapeutics (NASDAQ:MGEN) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking and earnings. Does the MarketBeat Community favor MGEN or XGN? Miragen Therapeutics received 239 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 70.45% of users gave Miragen Therapeutics an outperform vote while only 62.22% of users gave Exagen an outperform vote. CompanyUnderperformOutperformMiragen TherapeuticsOutperform Votes26770.45% Underperform Votes11229.55% ExagenOutperform Votes2862.22% Underperform Votes1737.78% Do insiders & institutionals believe in MGEN or XGN? 75.3% of Exagen shares are owned by institutional investors. 1.1% of Miragen Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, MGEN or XGN? Miragen Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Is MGEN or XGN more profitable? Exagen has a net margin of -30.36% compared to Miragen Therapeutics' net margin of -1,393.50%. Exagen's return on equity of -92.58% beat Miragen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Miragen Therapeutics-1,393.50% -141.66% -88.74% Exagen -30.36%-92.58%-33.74% Which has stronger valuation and earnings, MGEN or XGN? Exagen has higher revenue and earnings than Miragen Therapeutics. Exagen is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiragen Therapeutics$4.46M11.89-$41.87M-$20.09-0.68Exagen$56.72M2.56-$23.69M-$0.84-8.11 Does the media prefer MGEN or XGN? In the previous week, Exagen had 3 more articles in the media than Miragen Therapeutics. MarketBeat recorded 3 mentions for Exagen and 0 mentions for Miragen Therapeutics. Exagen's average media sentiment score of 0.63 beat Miragen Therapeutics' score of 0.00 indicating that Exagen is being referred to more favorably in the news media. Company Overall Sentiment Miragen Therapeutics Neutral Exagen Positive Do analysts rate MGEN or XGN? Exagen has a consensus target price of $7.50, indicating a potential upside of 10.13%. Given Exagen's stronger consensus rating and higher probable upside, analysts plainly believe Exagen is more favorable than Miragen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Miragen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Exagen 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryExagen beats Miragen Therapeutics on 13 of the 18 factors compared between the two stocks. Get Miragen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGEN vs. The Competition Export to ExcelMetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.03M$2.97B$5.38B$8.50BDividend YieldN/A31.25%5.28%4.16%P/E Ratio-1.2712.8527.0119.90Price / Sales11.89159.95392.03138.33Price / CashN/A57.5638.2534.64Price / Book2.004.416.774.56Net Income-$41.87M-$22.21M$3.22B$248.06M Miragen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGENMiragen TherapeuticsN/A$13.57-0.7%N/A+12.1%$53.03M$4.46M-1.2745Gap DownHigh Trading VolumeXGNExagen3.5783 of 5 stars$5.88-7.1%$7.50+27.6%+254.8%$125.24M$56.72M-6.26220Gap UpMDXHMDxHealth2.138 of 5 stars$2.20+6.3%$6.50+195.5%-25.3%$104.03M$94.51M-1.45300News CoverageAnalyst UpgradeGap UpSERASera Prognostics0.6327 of 5 stars$2.18-6.0%N/A-79.8%$82.50M$115,000.00-2.21120OPGNOpGenN/A$4.89flatN/A+42.4%$49.23M$2.67M0.00100Upcoming EarningsGap UpBDSXBiodesix3.3142 of 5 stars$0.28-7.6%$2.00+619.4%-76.4%$39.43M$71.32M-0.69220BNRBurning Rock Biotech0.4506 of 5 stars$2.96+8.6%N/A-56.6%$31.80M$515.82M-0.991,390News CoverageGap UpENZEnzo BiochemN/A$0.33-14.8%N/A-69.6%$17.03M$29.09M0.00520Gap DownHigh Trading VolumeBGLCBioNexus Gene Lab0.2082 of 5 stars$2.68-0.4%N/A-43.5%$4.82M$9.51M0.0030Negative NewsACONAclarion1.0224 of 5 stars$7.00-2.4%$11,758.50+167,878.6%-99.8%$4.07M$45,724.000.007NTRANatera3.1471 of 5 stars$154.01+0.5%$182.12+18.2%+40.0%$21.00B$1.83B-87.393,020Positive News Related Companies and Tools Related Companies Exagen Alternatives MDxHealth Alternatives Sera Prognostics Alternatives OpGen Alternatives Biodesix Alternatives Burning Rock Biotech Alternatives Enzo Biochem Alternatives BioNexus Gene Lab Alternatives Aclarion Alternatives Natera Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGEN) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MGEN Stock Free MGEN Stock Alerts